Evidence map›Paper›PMID 35365728›Full record

ArticleScientific reports2022

Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis.

David A Sheridan, Isaac Thom Shawa, E Louise Thomas, Daniel J Felmlee, Simon H Bridge, Dermot Neely, Jeremy F Cobbold, Elaine Holmes, Margaret F Bassendine, Simon D Taylor-Robinson

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Review
  5. Observational
  6. Review
  7. Review
  8. Article
  9. Article
  10. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.International journal of molecular sciences · 2024
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

David A SheridanHepatology Research Group, Faculty of Health, University of Plymouth, Plymouth, PL6 8BU, UK. david.sheridan@plymouth.ac.uk.
Isaac Thom ShawaHepatology Research Group, Faculty of Health, University of Plymouth, Plymouth, PL6 8BU, UK.
E Louise ThomasResearch Centre for Optimal Health, School of Life Sciences, University of Westminster, London, UK.
Daniel J FelmleeHepatology Research Group, Faculty of Health, University of Plymouth, Plymouth, PL6 8BU, UK.
Simon H BridgeFaculty of Health and Life Sciences, Northumbria University, Newcastle-upon-Tyne, NE1 8ST, UK.
Dermot NeelyDepartment of Clinical Biochemistry, Newcastle University Upon Tyne Hospitals NHS Trust, Newcastle-upon-Tyne, UK.
Jeremy F CobboldDepartment of Gastroenterology and Hepatology and The NIHR Oxford Biomedical Research Centre, The Oxford University Hospitals NHS Foundation Trust, The John Radcliffe Hospital, Oxford, OX3 9DU, Oxfordshire, UK.
Elaine HolmesDepartment of Metabolism, Digestion and Reproduction, Sir Alexander Fleming Building, Imperial College London, South Kensington Campus, London, UK.
Margaret F BassendineTranslational and Clinical Research Institute, The Medical School, Leech Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Simon D Taylor-RobinsonDepartment of Surgery and Cancer, Imperial College London, London, W2 1NY, UK.
Imperial College London · GBUniversity of Plymouth · GBNewcastle University · GBNewcastle upon Tyne Hospital · GBNorthumbria University · GBOxford BioMedica (United Kingdom) · GBUniversity of Westminster · GB

Funding

Medical Research Council G0502028Wellcome Trust
6 · The paper itself

Abstract

Lipids play essential roles in the hepatitis C virus (HCV) life cycle and patients with chronic HCV infection display disordered lipid metabolism which resolves following successful anti-viral therapy. It has been proposed that HCV genotype 3 (HCV-G3) infection is an independent risk factor for hepatocellular carcinoma and evidence suggests lipogenic proteins are involved in hepatocarcinogenesis. We aimed to characterise variation in host lipid metabolism between participants chronically infected with HCV genotype 1 (HCV-G1) and HCV-G3 to identify likely genotype-specific differences in lipid metabolism. We combined several lipidomic approaches: analysis was performed between participants infected with HCV-G1 and HCV-G3, both in the fasting and non-fasting states, and after sustained virological response (SVR) to treatment. Sera were obtained from 112 fasting patients (25% with cirrhosis). Serum lipids were measured using standard enzymatic methods. Lathosterol and desmosterol were measured by gas-chromatography mass spectrometry (MS). For further metabolic insight on lipid metabolism, ultra-performance liquid chromatography MS was performed on all samples. A subgroup of 13 participants had whole body fat distribution determined using in vivo magnetic resonance imaging and spectroscopy. A second cohort of (non-fasting) sera were obtained from HCV Research UK for comparative analyses: 150 treatment naïve patients and 100 non-viraemic patients post-SVR. HCV-G3 patients had significantly decreased serum apoB, non-HDL cholesterol concentrations, and more hepatic steatosis than those with HCV-G1. HCV-G3 patients also had significantly decreased serum levels of lathosterol, without significant reductions in desmosterol. Lipidomic analysis showed lipid species associated with reverse cholesterol transport pathway in HCV-G3. We demonstrated that compared to HCV-G1, HCV-G3 infection is characterised by low LDL cholesterol levels, with preferential suppression of cholesterol synthesis via lathosterol, associated with increasing hepatic steatosis. The genotype-specific lipid disturbances may shed light on genotypic variations in liver disease progression and promotion of hepatocellular cancer in HCV-G3.

Indexed as

HepacivirusHepatitis CCholesterolGenotypeHumansLipid MetabolismCholesterol

Identifiers

PMID35365728
PMCPMC8975940
OpenAlexW4220893878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.